AGFG1 and Miyoshi myopathy: We found that treatment with the TGF-β type I receptor kinase inhibitor Ki26894 in MM-bearing SCID-rab mice suppressed MM cell growth within the bone marrow while preventing bone destruction and loss (Figure 7).